Sarepta Therapeutics

JPM21: Biogen faces make-or-break year, Vertex mulls deals and Sarepta pitches a silver lining
JPM21: Biogen faces make-or-break year, Vertex mulls deals and Sarepta pitches a silver lining
BioPharma Dive
JPMHC 2021
Biogen
Vertex Pharmaceuticals
Sarepta Therapeutics
Flag link:
Sarepta's DMD gene therapy fails phase 2 motor function test, sinking stock
Sarepta's DMD gene therapy fails phase 2 motor function test, sinking stock
Fierce Biotech
Sarepta Therapeutics
Duchenne Muscular Dystrophy
clinical trials
SRP-9001
Flag link:
Pfizer beats Sarepta to the start of first late-stage Duchenne gene therapy trial
Pfizer beats Sarepta to the start of first late-stage Duchenne gene therapy trial
BioPharma Dive
Pfizer
Sarepta Therapeutics
clinical trials
Duchenne Muscular Dystrophy
gene therapy
Flag link:
Sarepta shares first results on next-generation Duchenne drug
Sarepta shares first results on next-generation Duchenne drug
BioPharma Dive
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-5051
Exondys 51
Flag link:
FDA gene therapy holdups suggest closer scrutiny by agency
FDA gene therapy holdups suggest closer scrutiny by agency
BioPharma Dive
FDA
gene therapy
Sarepta Therapeutics
Voyager Therapeutics
Iovance
Bluebird Bio
Flag link:
Sarepta partner Lysogene reports patient death in AAVance clinical trial
Sarepta partner Lysogene reports patient death in AAVance clinical trial
The Fly
Sarepta Therapeutics
Lysogene
patient deaths
clinical trials
gene therapy
Flag link:
New data bolsters Sarepta gene therapies for two deadly muscle diseases
New data bolsters Sarepta gene therapies for two deadly muscle diseases
Biopharma Dive
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
Limb Girdle Muscular Dystrophy
SRP-9001
SRP-9003
Flag link:
Sarepta faces another gene therapy hiccup as Regenxbio sues over Jim Wilson's patent
Sarepta faces another gene therapy hiccup as Regenxbio sues over Jim Wilson's patent
Endpoints
Sarepta Therapeutics
gene therapy
Regenxbio
Duchenne Muscular Dystrophy
Flag link:
Sarepta cites 'overburdened' FDA as factor in DMD gene therapy delay
Sarepta cites 'overburdened' FDA as factor in DMD gene therapy delay
Fierce Biotech
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
FDA
Flag link:
Sarepta shares fall on potential regulatory delay for experimental Duchenne drug
Sarepta shares fall on potential regulatory delay for experimental Duchenne drug
Marketwatch
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-9001
Flag link:
Sarepta Therapeutics Gets Fast-Track FDA Review For Muscular Dystrophy Drug
Sarepta Therapeutics Gets Fast-Track FDA Review For Muscular Dystrophy Drug
Investors Business Daily
Sarepta Therapeutics
FDA
fast track
Duchenne Muscular Dystrophy
casimersen
Flag link:
Sarepta bags drug to fully unlock DMD gene therapy opportunity
Sarepta bags drug to fully unlock DMD gene therapy opportunity
Fierce Biotech
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Hansa Biopharma
gene therapy
Flag link:
Sarepta expands gene therapy toolkit, bets $72.5M to hitch a ride on Codiak's exosome tech
Sarepta expands gene therapy toolkit, bets $72.5M to hitch a ride on Codiak's exosome tech
Endpoints
Sarepta Therapeutics
Codiak Biosciences
gene therapy
Flag link:
Sarepta, with new data, plans final push for limb-girdle gene therapy
Sarepta, with new data, plans final push for limb-girdle gene therapy
BioPharma Dive
Sarepta Therapeutics
Limb Girdle Muscular Dystrophy
gene therapy
SRPT-9003
Flag link:
FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs
FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs
Xconomy
Sarepta Therapeutics
Vyondys 53
Duchenne Muscular Dystrophy
FDA
Flag link:
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
Xconomy
Roche
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
SRP-9001
Flag link:
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
gene therapy
reimbursement
drug manufacturing
Bristol-Myers Squibb
Pfizer
Biomarin
Sarepta Therapeutics
Gilead Sciences
CAR-T
Flag link:
In stunning twist, FDA approves Sarepta's Duchenne drug it rejected
In stunning twist, FDA approves Sarepta's Duchenne drug it rejected
Biopharma Dive
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Vyondys 53
Flag link:
Wave faces key test in bid to challenge Sarepta in DMD
Wave faces key test in bid to challenge Sarepta in DMD
Biopharma Dive
Wave Life Sciences
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
Flag link:
Sarepta pays StrideBio $48M for preclinical gene therapies
Sarepta pays StrideBio $48M for preclinical gene therapies
Fierce Biotech
Sarepta Therapeutics
StrideBio
gene therapies
CNS
Flag link:

Pages